S&P 500   5,123.41 (-1.46%)
DOW   37,983.24 (-1.24%)
QQQ   438.27 (-1.59%)
AAPL   176.55 (+0.86%)
MSFT   421.90 (-1.41%)
META   511.90 (-2.15%)
GOOGL   157.73 (-1.05%)
AMZN   186.13 (-1.54%)
TSLA   171.05 (-2.03%)
NVDA   881.86 (-2.68%)
AMD   163.28 (-4.23%)
NIO   4.11 (-7.85%)
BABA   71.29 (-4.76%)
T   16.31 (-0.67%)
F   12.61 (-3.30%)
MU   122.52 (-3.91%)
GE   154.63 (-1.93%)
CGC   7.80 (-4.29%)
DIS   114.01 (-2.68%)
AMC   2.65 (-5.36%)
PFE   25.86 (-1.82%)
PYPL   64.59 (-1.84%)
XOM   120.37 (-1.17%)
S&P 500   5,123.41 (-1.46%)
DOW   37,983.24 (-1.24%)
QQQ   438.27 (-1.59%)
AAPL   176.55 (+0.86%)
MSFT   421.90 (-1.41%)
META   511.90 (-2.15%)
GOOGL   157.73 (-1.05%)
AMZN   186.13 (-1.54%)
TSLA   171.05 (-2.03%)
NVDA   881.86 (-2.68%)
AMD   163.28 (-4.23%)
NIO   4.11 (-7.85%)
BABA   71.29 (-4.76%)
T   16.31 (-0.67%)
F   12.61 (-3.30%)
MU   122.52 (-3.91%)
GE   154.63 (-1.93%)
CGC   7.80 (-4.29%)
DIS   114.01 (-2.68%)
AMC   2.65 (-5.36%)
PFE   25.86 (-1.82%)
PYPL   64.59 (-1.84%)
XOM   120.37 (-1.17%)
S&P 500   5,123.41 (-1.46%)
DOW   37,983.24 (-1.24%)
QQQ   438.27 (-1.59%)
AAPL   176.55 (+0.86%)
MSFT   421.90 (-1.41%)
META   511.90 (-2.15%)
GOOGL   157.73 (-1.05%)
AMZN   186.13 (-1.54%)
TSLA   171.05 (-2.03%)
NVDA   881.86 (-2.68%)
AMD   163.28 (-4.23%)
NIO   4.11 (-7.85%)
BABA   71.29 (-4.76%)
T   16.31 (-0.67%)
F   12.61 (-3.30%)
MU   122.52 (-3.91%)
GE   154.63 (-1.93%)
CGC   7.80 (-4.29%)
DIS   114.01 (-2.68%)
AMC   2.65 (-5.36%)
PFE   25.86 (-1.82%)
PYPL   64.59 (-1.84%)
XOM   120.37 (-1.17%)
S&P 500   5,123.41 (-1.46%)
DOW   37,983.24 (-1.24%)
QQQ   438.27 (-1.59%)
AAPL   176.55 (+0.86%)
MSFT   421.90 (-1.41%)
META   511.90 (-2.15%)
GOOGL   157.73 (-1.05%)
AMZN   186.13 (-1.54%)
TSLA   171.05 (-2.03%)
NVDA   881.86 (-2.68%)
AMD   163.28 (-4.23%)
NIO   4.11 (-7.85%)
BABA   71.29 (-4.76%)
T   16.31 (-0.67%)
F   12.61 (-3.30%)
MU   122.52 (-3.91%)
GE   154.63 (-1.93%)
CGC   7.80 (-4.29%)
DIS   114.01 (-2.68%)
AMC   2.65 (-5.36%)
PFE   25.86 (-1.82%)
PYPL   64.59 (-1.84%)
XOM   120.37 (-1.17%)

Titan Pharmaceuticals (TTNP) Competitors

$7.26
+0.10 (+1.40%)
(As of 05:22 PM ET)

TTNP vs. CHRO, TCON, CELZ, FRTX, NSTGQ, ALBT, FNCH, SRNE, ELOX, and KRBP

Should you be buying Titan Pharmaceuticals stock or one of its competitors? The main competitors of Titan Pharmaceuticals include Chromocell Therapeutics (CHRO), TRACON Pharmaceuticals (TCON), Creative Medical Technology (CELZ), Fresh Tracks Therapeutics (FRTX), NanoString Technologies (NSTGQ), Avalon GloboCare (ALBT), Finch Therapeutics Group (FNCH), Sorrento Therapeutics (SRNE), Eloxx Pharmaceuticals (ELOX), and Kiromic BioPharma (KRBP). These companies are all part of the "biological products, except diagnostic" industry.

Titan Pharmaceuticals vs.

Chromocell Therapeutics (NYSE:CHRO) and Titan Pharmaceuticals (NASDAQ:TTNP) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, community ranking, profitability, earnings, risk, analyst recommendations and media sentiment.

In the previous week, Titan Pharmaceuticals had 2 more articles in the media than Chromocell Therapeutics. MarketBeat recorded 3 mentions for Titan Pharmaceuticals and 1 mentions for Chromocell Therapeutics. Chromocell Therapeutics' average media sentiment score of 0.96 beat Titan Pharmaceuticals' score of 0.00 indicating that Titan Pharmaceuticals is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Chromocell Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Titan Pharmaceuticals
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Chromocell Therapeutics has a net margin of 0.00% compared to Chromocell Therapeutics' net margin of -2,021.31%. Titan Pharmaceuticals' return on equity of 0.00% beat Chromocell Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Chromocell TherapeuticsN/A N/A N/A
Titan Pharmaceuticals -2,021.31%-165.90%-105.75%

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Chromocell Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A
Titan Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A

78.0% of Chromocell Therapeutics shares are owned by institutional investors. Comparatively, 31.5% of Titan Pharmaceuticals shares are owned by institutional investors. 24.9% of Titan Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Titan Pharmaceuticals received 335 more outperform votes than Chromocell Therapeutics when rated by MarketBeat users.

CompanyUnderperformOutperform
Chromocell TherapeuticsN/AN/A
Titan PharmaceuticalsOutperform Votes
335
57.46%
Underperform Votes
248
42.54%

Chromocell Therapeutics has higher earnings, but lower revenue than Titan Pharmaceuticals.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Chromocell TherapeuticsN/AN/AN/AN/AN/A
Titan Pharmaceuticals$180K36.70-$5.57MN/AN/A

Summary

Titan Pharmaceuticals beats Chromocell Therapeutics on 5 of the 9 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TTNP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

TTNP vs. The Competition

MetricTitan PharmaceuticalsBiological Products IndustryMedical SectorNASDAQ Exchange
Market Cap$6.61M$2.46B$4.82B$7.65B
Dividend YieldN/A2.27%2.97%3.91%
P/E RatioN/A26.07215.8616.29
Price / Sales36.70343.592,405.1191.80
Price / CashN/A148.2736.2731.64
Price / Book0.824.024.584.30
Net Income-$5.57M-$20.14M$103.95M$214.66M
7 Day Performance5.99%-2.65%-2.14%-2.27%
1 Month Performance-9.14%-2.28%-1.80%-1.57%
1 Year Performance-53.47%20.36%17.27%9.91%

Titan Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CHRO
Chromocell Therapeutics
0 of 5 stars
$1.97
-8.4%
N/AN/A$7.64MN/A0.003Gap Down
TCON
TRACON Pharmaceuticals
1.3811 of 5 stars
$0.17
-10.6%
$3.00
+1,684.7%
-93.6%$7.65M$12.05M-0.6517Stock Split
Short Interest ↓
CELZ
Creative Medical Technology
1.0446 of 5 stars
$5.64
+2.0%
N/A+13.0%$7.67M$10,000.00-1.524Short Interest ↓
Positive News
FRTX
Fresh Tracks Therapeutics
0 of 5 stars
$0.88
-3.3%
N/A+60.1%$5.26M$10.06M-0.624Gap Up
NSTGQ
NanoString Technologies
0 of 5 stars
$0.09
flat
N/AN/A$4.17M$127.26M-0.02550Positive News
Gap Down
ALBT
Avalon GloboCare
0 of 5 stars
$0.37
+12.2%
N/A-85.6%$4.04M$1.23M0.005Short Interest ↓
High Trading Volume
FNCH
Finch Therapeutics Group
1.5536 of 5 stars
$2.46
+11.3%
N/A-79.4%$3.95M$110,000.00-0.0518Short Interest ↓
Gap Down
SRNE
Sorrento Therapeutics
0 of 5 stars
$0.02
+100.0%
N/A-90.4%$9.44M$60.32M0.00799Gap Down
ELOX
Eloxx Pharmaceuticals
0.3962 of 5 stars
$1.04
flat
$55.00
+5,188.5%
-89.9%$3.27MN/A-0.1118Gap Down
KRBP
Kiromic BioPharma
0 of 5 stars
$2.27
-3.4%
N/A-16.2%$2.93MN/A-0.1535Upcoming Earnings

Related Companies and Tools

This page (NASDAQ:TTNP) was last updated on 4/12/2024 by MarketBeat.com Staff

From Our Partners